On November 24, “Xuanwu geriatrics International Forum (2018)” was held in Beijing National Convention Center. Leaders of the Ministry of science and technology, the national health and Family Planning Commission, the Beijing Municipal Commission of science and technology and other institutions, experts of the international Geriatrics Society and domestic academicians, famous experts and scholars attended to explore a series of problems in the field of clinical research management of geriatrics in China.
At the Xuanwu International Forum on geriatrics held in November last year, the national geriatric disease clinical medicine research center established 12 clinical and scientific research cooperation alliances, including China Parkinson’s alliance.
There is still a gap in geriatric disease management in China
Due to the decline of physiological function, common senile diseases such as coronary heart disease, dementia, Parkinson’s disease, cerebrovascular disease and senile syndrome are “frequent guests” of the elderly group. By the end of 2017, China’s elderly population aged 60 and over had reached 241 million, accounting for 17.3% of the total population.
“Population aging is China’s new basic national condition at this stage and for a long time in the future.” Professor Chen Biao, director of the National Clinical Research Center for geriatric diseases and chairman of China Parkinson’s League, said. In this context, geriatrics has become the focus of medical attention.
Data show that modern geriatrics originated in Britain, while geriatrics in the United States focuses on the skills, independence and quality of life of the elderly as a whole, rather than a single disease. The characteristics include multi-level development, rehabilitation throughout the whole medical service system, and paying attention to the diagnosis and treatment of senile neuropsychiatric diseases. Compared with foreign countries, China still lacks a complete and hierarchical long-term care system, mostly based on the family pension model, and there are still gaps in chronic disease management, rehabilitation and spiritual care.
“Brain science” has been a “mysterious” existence in doctors and even medical circles since ancient times, and the diagnosis is very difficult and complex. Tracing back to the above many geriatric diseases, the intervention management needs to start with “brain specialty”.
Broken bureau geriatric Management: people gather firewood and the flame is high
Professor Chen Biao said that at present, the diagnosis of brain diseases in China is mostly based on the clinical experience of specialists. In the future, we must give full play to the role of the national clinical cooperation alliance, play a hierarchical role from the national to the regional and then to the provincial sub centers, and realize the management of common chronic diseases in the elderly. He said that the above-mentioned scientific research cooperation alliance is to realize the closed-loop scientific research and service nationwide through big data sharing.
The closed-loop scientific research undertakes a series of “tasks” such as clinical data collection, management, resource sharing, collaborative research, diagnosis and treatment test and technical training; In the closed-loop service, grass-roots doctors play the role of connecting patients and well-known experts. One is responsible for the chronic disease management of patients, and the other is connected with the consultation and referral of experts.
Professor Chen Biao is particularly optimistic about the remote consultation mode. “The management of Parkinson’s patients should be boundless and can break through the time limit. Improving the efficiency of diagnosis and treatment through Internet, hospitals and other carriers and remote consultation is a more effective way of Parkinson’s patient management in the future.” He said.
In addition to the promotion at the national level, in recent years, a wave of “Ai + medical” enterprises based on the combination of emerging technologies such as machine learning, artificial intelligence and big data analysis have poured into the industry, most of which are auxiliary decision-making systems based on medical images. In the field of brain science, there are also roles such as Meg, neuroquant and neuroreader.
Most of the businesses of such enterprises cut into the clinical and scientific research part of the hospital in the form of “auxiliary diagnosis system + analysis cloud platform”, providing a series of whole process services such as data collection, data modeling, data analysis and data application. Landing methods include cooperation with the government, colleges and hospitals to take the lead in obtaining massive images or pathological data and training algorithms to launch more accurate and competitive AI products.
Energy tipping point of “Ai + brain specialty” medical service
It is worth noting that the one-stop neuroimaging analysis cloud platform brain label developed by MEG, a high-tech enterprise, is the exclusive support platform of the National Clinical Research Center for geriatric diseases. As the big data bearing platform of the center in brain science and medicine, it is also responsible for the technical transformation of artificial intelligence brain specialty research.
Martin, founder of MEG, admitted that as a technology provider of “Ai + brain specialty” medical products, the biggest challenge of its products does not lie in the technology itself, but in technology transformation, that is, what value technology can really bring to Chinese doctors. Susumu mori, Professor of Radiology and oncology at Johns Hopkins University School of medicine, academician of the international magnetic resonance Association and chief scientist of MEG, told EU health that the success rate of technology transformation of a science and technology application in medical clinic is less than 1%. At present, the application of AI assisted diagnosis is still at the same level or lower than that of human doctors. In the future, such applications should aim at more difficult diseases that are difficult for human doctors to distinguish.
The imagination of new technology in brain specialist medical services is huge within the scope of medicine, but now, no matter the level of technological development or commercial landing, China’s AI + brain specialist medical services are still in a relatively early stage. So where are the opportunities in the future?
At the national level, centralize data collection, processing and management through cooperation modes such as “PPP” to facilitate the use of standards and norms. Professor Chen Biao said that through the brain label platform, the national geriatric disease clinical medicine research center will have the opportunity to provide more accurate data guidance for clinical and scientific research in the future.
At the enterprise level, Ma Ting’s view is that enterprises should not stop at product and technology providers, but should serve physical health care as a platform role. In the future, we will realize vertical and horizontal Services – open platform data interface, gather multidisciplinary forces in the industry and expand the types of diseases. In this regard, MEG is also marching in this direction: brain label has expanded its R & D capabilities of surgical planning, navigation and drug tracking, and the company is building the role of “scientific and technological products + special disease platform”.
Finally, in terms of scientific research, Susumu Mori told yiouda health that medical services between “Ai + brain specialty” need the participation of a large amount of information, including blood, gene, ECG and other image information. “Brain atlas” is a powerful assistant of machine learning. It structures unstructured data, which is of great significance for doctors’ scientific research and clinical auxiliary diagnosis.
The tide of aging is surging. How far can AI + brain specialty develop? How long will it take to mature? With the deepening application of ABCD (AI, blockchain, cloud, big data) technology in various industries and fields, perhaps we need to give the industry more time to wait for the interconnection of all things, the return of technologies, and the birth of the next closed-loop ecology.